| FET-PET Directed Simultaneous In-field Boost for Primary GBM (NCT04790097) | Prof. Franciszek Lukaszczyk Memorial Oncology Center | 2017-02-21 |
| Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting (NCT02717962) | Kintara Therapeutics, Inc. | 2017-01-20 |
| uPAR-PET/MRI in Glioblastoma Multiforme (NCT02945826) | Rigshospitalet, Denmark | 2017-01-01 |
| Adoptive Cell Therapy of Autologous TIL and PD1-TIL Cells for Patients With Glioblastoma Multiforme (NCT03347097) | Huashan Hospital | 2017-01-01 |
| mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme (NCT02619864) | Canadian Cancer Trials Group | 2016-12-22 |
| TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma (NCT02663271) | University of Florida | 2016-12-19 |
| A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) (NCT02974738) | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2016-12-07 |
| Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens (NCT02864368) | Eric Thompson, M.D. | 2016-12-07 |
| FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy (NCT03370926) | University Hospital, Brest | 2016-10-31 |
| Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients (NCT02933736) | Nader Sanai | 2016-10-17 |
| Ketogenic Diet Adjunctive to Salvage Chemotherapy for Recurrent Glioblastoma:a Pilot Study (NCT02939378) | Song Lin | 2016-10-01 |
| Temozolomide Chronotherapy for High Grade Glioma (NCT02781792) | Washington University School of Medicine | 2016-08-11 |
| Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme (NCT02465268) | University of Florida | 2016-08-09 |
| A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme (NCT02853565) | CANbridge Life Sciences Ltd. | 2016-08-01 |
| Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme (NCT02844062) | Beijing Sanbo Brain Hospital | 2016-07-01 |
| Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine (NCT02722512) | Ann & Robert H Lurie Children's Hospital of Chicago | 2016-07-01 |
| Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma (NCT02709226) | National Cancer Institute (NCI) | 2016-06-15 |
| Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma (NCT02715609) | Washington University School of Medicine | 2016-06-15 |
| Advanced Perfusion MRI of Treatment Response and Progression in Glioblastoma (NCT02769806) | University of Wisconsin, Madison | 2016-05-23 |
| Determination of Immune Phenotype in Glioblastoma Patients (NCT02751138) | University of Ulm | 2016-03-01 |
| Safety of IMRT Treatment With Inhomogeneous Dose in Patients With Relapsed High-grade Gliomas. (NCT04610229) | Azienda USL Reggio Emilia - IRCCS | 2016-02-01 |
| A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM) (NCT02586857) | Acerta Pharma BV | 2016-01-25 |
| Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab (NCT01931098) | National Cancer Institute (NCI) | 2015-12-10 |
| Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma (NCT02510950) | Washington University School of Medicine | 2015-12-03 |
| Cancer Stem Cell High-Throughput Drug Screening Study (NCT02654964) | Swedish Medical Center | 2015-12-01 |
| The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma (NCT02414165) | Tocagen Inc. | 2015-11-30 |
| Regorafenib in Relapsed Glioblastoma (NCT02926222) | Istituto Oncologico Veneto IRCCS | 2015-11-01 |
| A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies (NCT02498665) | Sumitomo Pharma America, Inc. | 2015-11-01 |
| DC Migration Study for Newly-Diagnosed GBM (NCT02366728) | Mustafa Khasraw, MBChB, MD, FRCP, FRACP | 2015-10-12 |
| Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors (NCT02502708) | NewLink Genetics Corporation | 2015-10-01 |
| INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme (NCT02386826) | SCRI Development Innovations, LLC | 2015-09-22 |
| Application of Proteome Profiler Antibody Arrays to Find Angiogenetic Predictors in Glioma Paitents. (NCT03225963) | Taichung Veterans General Hospital | 2015-08-01 |
| A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM) in Australia (NCT02507102) | Nativis, Inc. | 2015-08-01 |
| Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients (NCT02850744) | PIQUR Therapeutics AG | 2015-07-01 |
| A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma (NCT02026271) | Alaunos Therapeutics | 2015-06-01 |
| Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme (NCT02331498) | Centre Antoine Lacassagne | 2015-06-01 |
| Neoadjuvant Nivolumab in Glioblastoma (NCT02550249) | Clinica Universidad de Navarra, Universidad de Navarra | 2015-06-01 |
| Dose-Escalation Study of Carboplatin Administration Into the Brain for Glioblastoma Multiforme (NCT01317212) | North Bristol NHS Trust | 2015-05-01 |
| Fluorescein vs. iMRI in Resection of Malignant High Grade Glioma (NCT02540135) | University of Colorado, Denver | 2015-03-01 |
| Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM (NCT02780024) | McGill University Health Centre/Research Institute of the McGill University Health Centre | 2015-03-01 |
| A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor (NCT02365662) | AbbVie | 2015-01-09 |
| Evaluating Therapeutic Response to Novo-TTF (NCT02441322) | Abramson Cancer Center at Penn Medicine | 2014-12-01 |
| Glioma Modified Atkins-based Diet in Patients With Glioblastoma (NCT02286167) | Wake Forest University Health Sciences | 2014-11-01 |
| A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002) (NCT02296476) | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2014-10-29 |
| Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies (NCT02223052) | Celgene | 2014-10-27 |
| Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme (NCT02177578) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2014-07-08 |
| Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme (NCT02285959) | Global Neurosciences Institute | 2014-06-01 |
| The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma (NCT02189109) | NuvOx LLC | 2014-05-01 |
| Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme (NCT02078648) | Stemline Therapeutics, Inc. | 2014-05-01 |
| Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma (NCT02176720) | The Methodist Hospital Research Institute | 2014-05-01 |
| A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma (NCT01562197) | Bart Neyns | 2014-04-01 |
| Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma (NCT01811992) | University of Michigan Rogel Cancer Center | 2014-04-01 |
| Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors (NCT02052648) | NewLink Genetics Corporation | 2014-03-01 |
| Efficacy Study of Oral Arginine to Improve Immune Function in Glioblastoma Multiforme (NCT02017249) | Inova Health Care Services | 2014-03-01 |
| INTRAGO-Intraoperative Radiotherapy for Glioblastoma - a Phase I/II Study (NCT02104882) | Universitätsmedizin Mannheim | 2014-03-01 |
| Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma (NCT02067156) | GenSpera, Inc. | 2014-02-01 |
| A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM) (NCT02296580) | Nativis, Inc. | 2014-02-01 |
| Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan (NCT02060955) | CytoVac A/S | 2014-02-01 |
| Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor (NCT01985256) | Tocagen Inc. | 2014-02-01 |
| Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma (NCT02010606) | Cedars-Sinai Medical Center | 2014-01-08 |
| Phase I Study of Safety and Immunogenicity of ADU-623 (NCT01967758) | Providence Health & Services | 2014-01-08 |
| Efficacy and Safety of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma (NCT02029573) | King Fahad Medical City | 2014-01-01 |
| Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy (NCT02047214) | Cortice Biosciences, Inc. | 2014-01-01 |
| A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma (NCT02049489) | Precision Life Sciences Group | 2013-12-01 |
| Immunophenotyping From Blood of Patients With Malignant Gliomas (NCT02022384) | University of Erlangen-Nürnberg Medical School | 2013-12-01 |
| CT Perfusion in the Prognostication of Cerebral High Grade Glioma (NCT01923922) | Nova Scotia Health Authority | 2013-09-09 |
| Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors (NCT01902771) | Edward Ziga | 2013-09-03 |
| Virus DNX2401 and Temozolomide in Recurrent Glioblastoma (NCT01956734) | Clinica Universidad de Navarra, Universidad de Navarra | 2013-09-01 |
| Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma (NCT01808820) | Macarena De La Fuente, MD | 2013-08-21 |
| Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma (NCT01933815) | Cortice Biosciences, Inc. | 2013-08-01 |
| Engagement of Patients With Advanced Cancer (NCT02966509) | Stanford University | 2013-08-01 |
| Impact of [11C]-Methionine PET/MRI for Individual Tailoring Postoperative Radiochemotherapy for Glioblastoma Multiforme (NCT01873469) | Technische Universität Dresden | 2013-07-01 |
| Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 (NCT01884740) | Weill Medical College of Cornell University | 2013-06-01 |
| BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM) (NCT01856933) | Heinrich Elinzano, MD | 2013-05-01 |
| Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme (NCT01800695) | AbbVie | 2013-04-02 |
| A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme (NCT01752491) | Joseph J. Cullen, MD, FACS | 2013-04-01 |
| An Observational Study of Avastin (Bevacizumab) in Patients With Glioblastoma Multiforme in First or Second Relapse (NCT01618747) | Hoffmann-La Roche | 2013-03-15 |
| Re-irradiation of High Grade Gliomas: a Quality of Life Study (NCT01711580) | Maastricht Radiation Oncology | 2013-03-01 |
| Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM (NCT01811498) | Northwell Health | 2013-02-01 |
| FET-PET for Evaluation of Response of Recurrent GBM to Avastin (NCT01756352) | Marcelo F. Di Carli, MD, FACC | 2013-02-01 |
| Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot Study (NCT01865162) | Mid-Atlantic Epilepsy and Sleep Center, LLC | 2013-01-01 |
| Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer (NCT01631552) | Gilead Sciences | 2012-12-17 |
| TRC105 for Recurrent Glioblastoma (NCT01778530) | National Cancer Institute (NCI) | 2012-12-01 |
| Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma (NCT02928575) | Bassam Abdulkarim | 2012-08-01 |
| NOA-12: BIBF1120 and R-RT in Glioblastoma (NCT01666600) | Prof. Dr. Wolfgang Wick | 2012-08-01 |
| Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM) (NCT01587144) | Spectrum Pharmaceuticals, Inc | 2012-06-19 |
| A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma (NCT01564914) | Tracon Pharmaceuticals Inc. | 2012-05-01 |
| PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404 (NCT01540513) | University of Wisconsin, Madison | 2012-03-01 |
| Study of DC Vaccination Against Glioblastoma (NCT01567202) | Huashan Hospital | 2012-03-01 |
| Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor (NCT01470794) | Tocagen Inc. | 2012-02-01 |
| AMG 595 First-in-Human in Recurrent Gliomas (NCT01475006) | Amgen | 2012-02-01 |
| Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide (NCT01478854) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2011-12-27 |
| Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme (NCT01435395) | Emory University | 2011-12-01 |
| Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme (NCT01349660) | SCRI Development Innovations, LLC | 2011-12-01 |
| BG & TMZ Therapy of Glioblastoma Multiforme (NCT01269424) | Stanton Gerson MD | 2011-11-22 |
| A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma (NCT01474239) | Hoffmann-La Roche | 2011-11-01 |
| AZD7451 for Recurrent Gliomas (NCT01468324) | National Cancer Institute (NCI) | 2011-10-05 |
| Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence (NCT01526837) | Brain & Spine Surgeons of New York | 2011-10-01 |
| Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma (NCT01478178) | Kintara Therapeutics, Inc. | 2011-10-01 |
| Bevacizumab and Lomustine for Recurrent GBM (NCT01290939) | European Organisation for Research and Treatment of Cancer - EORTC | 2011-10-01 |